Fibronectin Mediates Endothelial-to-Mesenchymal Transition in Retina Angiogenesis
Investigative Ophthalmology & Visual Science · 2025
DOI: 10.1167/iovs.66.3.10 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, 2025. Written by Dan Liu and 8 co-authors. Institution: Department of Ophthalmology, Hunan Key Laboratory of Ophthalmology, Xiangya Hospital, Central South University, Changsha, China. Major MEDLINE topics: Fibronectins, Retinal Neovascularization, Epithelial-Mesenchymal Transition, Gene Expression Regulation. Cited 15 times so far (Crossref); 46 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Purpose
The purpose of this study was to investigate the role of endothelial-mesenchymal transition (EndoMT) in pathological retinal angiogenesis and identify key molecular mediators in retina angiogenesis.
Methods
RNA sequencing (RNA-seq) was performed on retinal tissue from an oxygen-induced retinopathy (OIR) mouse model to analyze gene expression patterns. The Gene Set Enrichment Analysis was used to examine the correlation between epithelial-mesenchymal transition (EMT) and angiogenesis gene sets. Fibronectin (FN1) expression was evaluated in endothelial cells, and its function was assessed through siRNA-mediated knockdown in both in vitro angiogenesis assays and the OIR model.
Results
EndoMT occurred early in retinal angiogenesis development, with significant correlation between EMT and angiogenesis gene sets. FN1 was identified as the most significantly upregulated EMT-related gene in endothelial cells. The siRNA-mediated inhibition of fibronectin effectively prevented VEGF-induced angiogenesis in vitro and reduced pathological angiogenesis in the OIR model.
Conclusions
EndoMT is a crucial early event in pathological retinal angiogenesis, with fibronectin serving as a key mediator. Targeting fibronectin may provide a novel therapeutic strategy that could synergize with anti-VEGF treatments to more effectively treat pathological angiogenesis in diabetic retinopathy (DR) and retinopathy of prematurity (ROP), particularly in cases of poor response to anti-VEGF therapy alone.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Ophthalmology, Hunan Key Laboratory of Ophthalmology, Xiangya Hospital, Central South University, Changsha, China.
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, China.
- Department of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, China.
- Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
- Huan Key Laboratory of Molecular Precision Medicine, Xiangya Hospital and Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Central South University, Changsha, China.
- Department of Pathology, Xiangya Hospital, Central South University, Changsha, China.
Cite
APA
Liu, D., Meng, Z., Jin, C., Chen, F., Pu, L., Wu, Z., Zeng, Q., Luo, J., & Wu, W. (2025). Fibronectin Mediates Endothelial-to-Mesenchymal Transition in Retina Angiogenesis. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.66.3.10
Vancouver
Liu D, Meng Z, Jin C, Chen F, Pu L, Wu Z, et al. Fibronectin Mediates Endothelial-to-Mesenchymal Transition in Retina Angiogenesis. Investigative Ophthalmology & Visual Science. 2025. doi:10.1167/iovs.66.3.10
BibTeX
@article{Liu2025,
author = {Liu, Dan and Meng, Zhishang and Jin, Chen and Chen, Fang and Pu, Li and Wu, Ze and Zeng, Qi and Luo, Jing and Wu, Wenyi},
title = {Fibronectin Mediates Endothelial-to-Mesenchymal Transition in Retina Angiogenesis},
journal = {Investigative Ophthalmology & Visual Science},
year = {2025},
doi = {10.1167/iovs.66.3.10}
}
EUVIMED